DexCom (DXCM) Director Nicholas Augustinos Sells Shares

What Happened

• Nicholas Augustinos, a director of DexCom, sold a total of 8,089 shares in two open-market transactions: 1,550 shares on 2026-09-14 at $84.02 ($130,231) and 6,539 shares on 2026-09-15 at $84.04 ($549,538), for combined proceeds of $679,769. These were sales (not purchases) executed pursuant to a pre-established 10b5-1 plan.

Key Details

• Transaction dates and prices:
  • 2026-09-14: Sold 1,550 shares @ $84.02 = $130,231
  • 2026-09-15: Sold 6,539 shares @ $84.04 = $549,538
• Shares owned after the transactions: Not specified in the filing.
• Notable footnotes:
  • F1: Sales were made under a 10b5-1 trading plan adopted June 10, 2026 (orderly disposition).
  • F2: Some shares are held by the Kirschner/Augustinos Revocable Trust, for which the reporting person is a trustee.
  • F3: The filing also references unvested restricted stock units granted May 28, 2026 that vest on the earlier of the one-year grant anniversary or DexCom’s 2027 annual meeting.
• Filing timing: Form 4 filed 2026-09-16 reporting transactions on 2026-09-14 and 2026-09-15; the filing appears timely (no late-file flag reported).

Context

• These were sales under a 10b5-1 plan, which typically represent pre-scheduled, orderly dispositions rather than ad hoc trades; such sales are generally treated as routine liquidity actions rather than a direct signal of management’s view on company prospects.
• Because this was a sale (transaction code S), it should be interpreted as liquidation of holdings, not an indication of increased confidence that a purchase might signal.